Form 4: Entrada Therapeutics Director Peter S. Kim Increases Stake in Company

Director Peter S. Kim of Entrada Therapeutics, Inc. [TRDA] recently purchased additional shares of common stock, increasing his beneficial ownership.

Summary

• On May 8, 2024, Peter S. Kim, a director of Entrada Therapeutics, Inc., purchased 2,276 shares of common stock at a weighted average price of $14.0442.
• These purchases were made in multiple transactions with prices ranging from $13.81 to $14.19.
• Following this transaction, Kim's direct ownership increased to 65,212 shares.
• On May 9, 2024, Kim purchased an additional 2,200 shares of common stock at a weighted average price of $14.2459.
• These purchases were made in multiple transactions with prices ranging from $14.11 to $14.44.
• Following this transaction, Kim's direct ownership increased to 67,412 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director purchasing shares usually indicates confidence, but it's a routine transaction.

Positives

• A director increasing their stake in the company can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders.

Stakeholder Impact

• The increased stake of a director may positively influence shareholder confidence.

Key Dates